MULTIMODALITY AND MULTIPARAMETRIC IMAGING
IN ADVANCING HEALTHCARE
TOWARDS PERSONALIZED MEDICINE ______________________________________________________________________
Following the previously conducted symposia on dedicated medical imaging instrumentation we are presently organizing the 5th workshop of this exclusive series to be held in the East of the beautiful island of Sardinia.
The purpose of this meeting is to discuss the role of the multimodality and multi-parametric imaging modalities on the vision of individualized/personalized medicine.
Based on the breakthroughs in genomic, proteomic and metabolic profiling Precision Medicine has emerged as a novel health-care paradigm. Precision Medicine is an approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle. It involves integrating information from multiple sources to achieve a precise diagnosis, personalized target treatment, and adequate response assessment.
The “-omics” analysis as well as histopathology are important input parameters for a precise diagnosis, however, as they rely on small biopsy samples or body fluids, they do usually not map the entire profile of the disease. Tumors typically have a spatially and temporally varying molecular and genetic profile; the same applies to neurodegenerative, cardiovascular or autoimmune diseases. Therefore, “liquid diagnostic parameters” can provide only a snapshot of the entire disease while Multiparametric Imaging can holistically map molecular, functional and habitant varieties of the same or multiple diseases.
Thus, Multiparametric Imaging and Imaging-Guided Interventions, which provide multiparametric information and enable focused, minimally invasive treatments, are key elements of complex Precision Diagnosis and Personalized Medicine. Different diagnostic approaches utilizing bioinformatics, machine learning, and systems biology will be used to mine the essential information and fuse the precise but spatially and temporally restricted disease characterization of “-omics” and histopathology with the holistic data of Multiparametric Imaging. The emerging fields of Radiomics and Radiogenomics are linking genotypic information to phenotypic disease manifestations from imaging. Because of the growing volume and complexity of imaging data and its necessary linkage to metadata, decision-support algorithms will be required to help physicians applying the most essential patient data for optimal management.
Based on the above emerging realities the MEDAMI Forum series of events is trying to define the role of and needs for Multiparametric Imaging in the development of healthcare towards Personalized/Precision Medicine and to determine the impact of those developments on collaboration- and business models in the future.
What are the key questions the MEDAMI 2017 will address?
Personalized Medicine – what will be the impact of what? on current medical imaging and image guided interventions? Is there a need for organ specific (precision) medical imaging?
Which medical areas have the the strongest impact/needs?
Are there new imaging technologies and methods for precision imaging?
In which areas are new biomarkers and imaging agents needed? What shall be the role of such new tracers and imaging agents in personalized medical imaging?
What funding mechanisms can be employed for the development of imagers and imaging agents that finally lead to widespread clinical application? What are the roles of funding agencies and industry?
How does Personalized Medicine impact the business models of stakeholders (industries, clinics, health care providers)?
The program of the MEDAMI 2017 is being developed . A number of Key Opinion Leaders (KOL’s) from Biology, Medicine and Technology fields have already been contacted to give lectures.
The program of the forum primarily will consist of invited talks by key opinion leaders and experts from around the world. However, a limited number of abstracts for oral or poster presentations will be accepted. If you have to report on a topic that you think fits into the scope of the program we will be happy to receive your abstract.
Preliminary list of key speakers who accepted to come and talk:
- Prof. Roderic Pettigrew, director of the National Institute of Biomedical Imaging and Bioengineering (NIBIB)- USA
- Prof. David Townsend, National University of Singapore, inventor of PET/CT
- Prof. Craig Levin, Stanford Molecular Imaging Instrumentation Laboratory (MIIL) – USA
- Prof. Bernd Pichler, University of Tubingen (Germany)
The meeting format fosters a close interaction between different stakeholders from academia, medical institutions and organizations, regulatory agencies and industry.
Nicolas Petrick (Center for Devices and Radiological Health (CDRH), Food and Drug Administration (FDA)) - FDA perspective on the role of FDA in the emerging field of precision medicine medical imaging
Abstract
2
Bernd Stowasser (Sanofi-Aventis, on behalf of the European Federation of Pharmaceutical Industries and Associations (EFPIA)) - Academic-Industry partnership: Can the IMI PPP model be extended/exported to medical imaging industry?
Session 1.2: Research concepts/activities (Moderator: York Haemisch)
3
Piotr Maniawski (Philips Healthcare, on behalf of the Association of Imaging Producers and Equipment Suppliers (AIPES)) - The AIPES organization and its role in supporting medical imaging development
Abstract
4
Marco Paganoni (Univ. of Milano) - ERAMIT
Abstract
5
Maurizio Conti (Siemens Healthineers, Knoxville) - Challenges and trends in molecular imaging, an industry research viewpoint. The role of radiotracers in modern diagnosis and expensive/advanced therapies
12:00 PM
Lunch break
Poster Session
Session 1.3: Diagnostic Imaging, theranostics and the -omics (Moderators: Bernd Pichler, Jonathan Disselhorst)
6
David Townsend (National University of Singapore) - PET/CT, PET/MR and Precision Medicine: some alternative facts
7
Bernd Pichler (Dept. of Pre-clinical imaging and Radiopharmacy University of Tuebingen) - Combining multiparametric imaging data with –omics information for precision medicine
8
Constantin Lapa (Nuclear Medicine, University of Wurzburg) - Theranostics and multimodality imaging
Abstract
4:15 PM
Coffee break
Session 1.3 (cont)
9
Jonathan A. Disselhorst (University Tuebingen) - Imaging Tumor Heterogeneity
Abstract
10
P. Pevsner - How cost-effectiveness of a diagnostic medical imaging procedure is determined
11
Roderic Pettigrew (Director of the National Institute of Biomedical Imaging and Bioengineering (NIBIB)) - Multimodality/Multiparametric Imaging and Precision Medicine
ROUND TABLE - The relation of academia and industry in the development of medical and molecular imaging technologies. Chair: Paul. Lecoq, CERN - Representatives of funding institutions, industries, MDs, physicists/technologists Outcome: proposals for improvement of academia-industry relation
Session 2.1: Neurodegenerative diseases and brain disorders
12
Charles R.G. Guttman (Center for Neurological Imaging, Harvard Medical School) - Neurodegenerative diseases - an overview
Abstract
13
Valentina Garibotto (Univ.of Geneva) - Multimodal/multiparamenter imaging – main modalities and applications: link to biomarkers and personalized medicine
Abstract
Slides
14
Martin Walter (University of Tuebingen, Germany) -Multimodal imaging in psychiatry
15
Vesna Sossi (University of British Columbia) - PET/MRI imaging in neurodegeneration: novel metrics for early disease detection and effect of therapy assessment
Abstract
10:30 AM
Lunch break
Session 2.2: Brain biomarkers and brain imaging initiatives
16
Christer Halldin (Karolinska Institutet, Stockholm) - PET Radioligands for Neuroscience and Drug Development
Abstract
Slides
17
Ilan Rabiner (Chief Medical Officer, Head of Imaging Applications, Imanova Ltd., UK) - Building the Three Pillars- Imaging in early phase drug development
Abstract
18
Paul M. Matthews (Head of Brain Imaging Sciences, Imperial College, London) - Challenges and opportunities for brain imaging with large population datasets
Abstract
19
Simone Sarasso (Dept. of Biomedical Sciences, University of Milano) - Major brain initiatives
1:00 PM
Lunch break
Poster Session
Session 2.3: Brain imaging - new technologies
20
Stan Majewski (University of Virginia) - Dedicated PET brain imaging devices
Abstract
21
Bernd Pichler (Director, Dept. of Pre-clinical imaging and Radiopharmacy, University of Tuebingen) - Developments in MRI, MEG and EEG
4:50 PM
Coffee break
Session 2.3: Brain imaging - new technologies
22
Jose Maria Benlloch (Institute of Molecular Imaging, University of Valencia) - Mindview: multimodal imaging of neurological disorders
23
Alberto del Guerra (Department of Physics, University of Pisa) - A trimodality (EEG/MR/PET) scanner for brain imaging
Abstract
Slides
24
Contributions
ROUND TABLE - Molecular imaging and -omics: competition or complementarity for Precision medicine? Chair: Vesna Sossi, UBC, Vancouver Representatives of funding institutions, industries, MDs, physicists/technologists
Session 3.1: New Technologies for Molecular Imaging
25
Paul Lecoq (CERN, Geneva) - The 10 ps TOF-PET challenge
26
Dennis Schaart (Department of Rad. Science & Technology, TU Delft) - Fundamentals of Ultrafast Timing
Abstract
27
Terry Jones (UCL, London) - The Explorer project: a new paradigm in nuclear medicine?
Abstract
28
Piotr Maniawski (Philips Healthcare, Cleveland) - Digital Photon Counting PET: technology powering precision molecular imaging
Abstract
10:25 AM
Coffee break
Session 3.1 (cont)
29
Bipin Singh (RMD Watertown, Ma) - Photonic Crystal Enhances Scintillation Light Extraction: Can It Improve Timing Resolution?
Abstract
Slides
30
Claudio Piemonte (FBK Trento) - New high performance SiPM arrays with TSV technology for TOF and other applications
31
Stefaan Tavernier (PETsys Electronics SA, Lisbon) - TOFPET II: The next generation ASIC for TOF-applications
Abstract
32
Gabriela Llosa (Instituto de Fisica Corpuscular, University of Valencia) - From MACACO to MACACO II: a Compton telescope for hadron therapy treatment monitoring
Abstract
Slides
33
Ilaria Mattei (INFN Milano) - Characterisation of the secondary fast and ultrafast neutrons emitted in Particle Therapy with the MONDO experiment
Abstract
12:40 PM
Lunch break
Poster Session
Session 3.2: Molecular Imaging in the diagnosis, treatment and follow up of breast cancer
34
Orazio Schillaci (TOV Policlinico Tor Vergata, Roma) - The role of Nuclear Medicine in breast cancer management
Abstract
35
Michael O’ Connor (Mayo Clinic Rochester) - Breast cancer screening with single gamma and positron emitters
4:30 PM
Coffee break
Poster Session
Session 3.3: Technologies for breast imaging/diagnosis
36
Evaristo Cisbani (ISS and INFN, Roma) - A novel SPECT-Thomosynthesis detector for the diagnosis and follow up of breast cancer
37
Michel Herranz (Univ. of Santiago de Compostela) - Dedicated breast PET (dbPET) in diagnosis and follow up of breast cancer - comparison, synergies and divergences with MRI
38
Volkmar Schulz (University of Aachen, DE) - PET-MR dedicated detector for breast cancer diagnosis and follow – up
Abstract
ROUND TABLE - Multimodality multiparametric imaging in cancer management: How can it be improved? (Chair: David Townsend, Singapore)
Session 4.1: Molecular Imaging in the management of prostate cancer
39
H. Van der Pohel (Amsterdam, Ne) - Multimodality imaging in surgery
Abstract
40
Tobias Maurer (Klinikum rechts der Isar, TU Munich) - Shifting gears in Imaging - how PSMA-PET is about to change prostate cancer diagnosis
Abstract
41
Valeria Panebianco (Università degli Studi di Roma La Sapienza) - The role of multiparametric MR in the diagnosis and follow up of prostate cancer
42
Paul Lecoq (CERN, Geneva) - ENDO-TOF-PET-US in the diagnosis and follow up of prostate cancer
9:40 AM
Coffee break
Session 4.1: Molecular Imaging in the management of prostate cancer
43
Franco Garibaldi (AIB, Roma) - TOF-PET-MR in the diagnosis and follow up of the prostate cancer
44
Nicoletta Protti (INFN Pavia) - In vivo 10B imaging and dose rate measurement for Boron Neutron Capture Therapy (BNCT) using Single Photon Emission Computed Tomography (BNCT-SPECT)
Session 5.1: Molecular Imaging in surgical interventions
45
Fijs van Leuven (LUMC, Leiden) - Multimodality imaging techniques in surgery
Slides
46
Tobias Maurer (Klinikum rechts der Isar, TU Munich) - PSMA radioguided surgery – a novel technique for intraoperative detection of prostate cancer metastases
47
Elena Solfaroli (Università degli Studi di Roma La Sapienza) - Radioguided surgery with beta-radiation: test on ex-vivo specimen
Abstract
Slides
48
Image guided robotic surgery in lung cancer. (... to be decided)
9:25 AM
Coffee break
Session 5.2: Molecular Imaging in Hadron Therapy Monitoring
49
P. Cerello (INFN Torino) - Imaging in hadron therapy
Abstract
50
F. Pennazio, INFN Torino) - The INSIDE project: hadron therapy monitoring with in-beam PET
Abstract
Slides
51
Ilaria Mattei (INFN Milano) - Study of the radiation produced by therapeutic He, C and O ion beams impinging on a PMMA target for beam range monitoring purpose in Particle Therapy